BeOne Medicines Ltd. - Sponsored ADR
BeOne Medicines Ltd. - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $5.3 billion, up 40.2% from fiscal 2024.
- Revenue
- +33.8%
- EPS
- +143.7%
- Free cash flow
- +33.6%
- Total debt
- +491.3%
Quarter to September 2026, against a year earlier
Follow ONC
Alert me
BeOne Medicines Ltd. - Sponsored ADR (ONC) Current ratio
BeOne Medicines Ltd. - Sponsored ADR's current ratio at the end of the quarter to 30 September 2026 was 3.6×, up 0.1× from fiscal 2025 (3.4×). Over the past ten years it has ranged from 1.8× (fiscal 2024) to 10.7× (fiscal 2016); the current reading is higher than 36% of that period. That is below the Biotechnology industry median of 4.9× and above the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 3.4× | 89.13% |
| FY2024 | 1.8× | (22.39%) |
| FY2023 | 2.3× | (34.51%) |
| FY2022 | 3.5× | (25.51%) |
| FY2021 | 4.8× | 3.17% |
| FY2020 | 4.6× | 22.08% |
| FY2019 | 3.8× | (52.09%) |
| FY2018 | 7.9× | 29.50% |
| FY2017 | 6.1× | (42.97%) |
| FY2016 | 10.7× | 253.46% |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Sep 2026 | 3.6× | 4.27% |
| Jun 2026 | 3.4× | (6.56%) |
| Mar 2026 | 3.6× | 6.91% |
| Dec 2025 | 3.4× | 42.51% |
| 41 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| ROIV Roivant Sciences Ltd. compare | 16.7× |
| BNTX BioNTech SE Sponsored ADR compare | 8.6× |
| RVMD Revolution Medicines, Inc. compare | 8.4× |
| ARGX argenex SE compare | 5.1× |
| INCY Incyte Corporation compare | 3.8× |
| ONC BeOne Medicines Ltd. - Sponsored ADR | 3.6× |
| INSM Insmed, Inc. compare | 2.9× |
| GMAB Genmab A/S Sponsored ADR compare | 2.5× |
| RPRX Royalty Pharma PLC compare | 1.3× |
| Biotechnology industry median | 4.9× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on ONC
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement